New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:43 EDTVRTXVertex shares should be owned ahead of data, says JMP Securities
JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2015
13:34 EDTVRTXGilead paying premium to buy Vertex not warranted right now, says Maxim
After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.
12:33 EDTVRTXOn The Fly: Top stock stories at midday
Subscribe for More Information
12:21 EDTVRTXVertex rises after Bernstein suggests Gilead should pursue takeover
Subscribe for More Information
08:14 EDTVRTXGilead should buy Vertex, says Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use